Background/Aim: Malnutrition and inflammation are common conditions in patients with head and neck cancer (HNC). This study aimed to evaluate the predictive value of albumin combined with neutrophil-lymphocyte ratio (NLR), referring to the albumin-NLR score (ANS), in the prediction of treatment completeness and safety profiles in HNC patients receiving definitive concurrent chemoradiotherapy (CCRT). Patients and Methods: 461 consecutive HNC patients who received CCRT between 2016 and 2017 at three medical centers in Taiwan were prospectively enrolled and divided into three different groups based on their pretreatment ANS (ANS 0, high albumin and low NLR; ANS 1, low albumin or high NLR; and ANS 2, low albumin and high NLR) for treatment completeness and safety profiles comparison. Results: Overall, 46 patients (10.0%) had incomplete CCRT treatment. Patients in the ANS 2 group experienced a higher rate of incomplete CCRT (20.9%) than those in the ANS 1 (7.4%) and ANS 0 (3.5%) groups. ANS had a better discriminatory ability in predicting CCRT completeness in terms of -2 log-likelihood value, chisquare value, and c-index than the prognostic nutritional index. Patients in the ANS 2 group had significantly higher incidences of grade 3 or higher leukopenia, anemia, neutropenia, thrombocytopenia, non-neutropenic infection, and hypokalemia than those in the other two ANS groups.
Conclusion: Our study showed that the ANS can accurately predict the treatment completeness of CCRT in patients with HNC and can be widely used as a simple predictor of treatment tolerance and safety profiles in patients with HNC undergoing CCRT.More than 60% of head and neck cancers (HNC) are diagnosed with locally advanced disease (1), for which radical resection does not lead to a cure. The overall 5-year survival for the advanced stages is 40%-50% and has not markedly improved in the past decades due to the frequent relapse at the primary site, distant metastases, and second primary tumors after definitive treatment (2, 3).Definitive concurrent chemoradiotherapy (CCRT) with a platinum-based regimen is currently the standard of care for patients with locally advanced HNC (4). However, grade 3 or higher grade serious adverse events (SAEs) are common in patients receiving definitive CCRT, including 41%-47% incidence of stomatitis, 37%-43% of dysphagia, 35% of odynophagia, 20%-32% of nausea or vomiting, and 15% of neutropenia (4-7). Because of the high toxicity profiles of CCRT, dose reduction of chemotherapeutic agents is common, and 6%-17% of patients fail to complete the planned CCRT (4-7), which inevitably compromises the treatment efficacy of CCRT. Therefore, avoidance of 2875